Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More

globenewswire.com
ILMN Mentioned as a key player in the Canada Next-Generation Sequencing (NGS) market, indicating its involvement in a growing industry. No specific positive or negative performance indicators are provided. ONTF Highlighted for its portable NGS devices like the MinION, which present a transformative opportunity for point-of-care diagnostics in Canada, especially in remote areas. This suggests a positive impact and future growth potential. PACB Listed as a prominent name in the Canada Next-Generation Sequencing (NGS) market. The article does not provide specific details on its performance or outlook within this market.

Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: Focus on Application, Technology, Offering, End User, and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The Canada next-generation sequencing (NGS) market is projected to reach $2.77 billion in 2035 and was estimated to be $381.6 million in 2023, growing at a CAGR of 19.40% during the forecast period 2025-2035. This growth is driven by several key factors. The increasing adoption of NGS-based testing in the treatment of cancer is particularly significant, as precision medicine continues to gain prominence in oncology, offering personalized treatment based on genetic profiles. Additionally, rising government initiatives, including funding and research programs, are fostering an environment conducive to the advancement of genomic technologies.

Furthermore, NGS is finding growing applications in healthcare and research, particularly in genetic testing and infectious disease monitoring, which has been highlighted by its role in tracking the spread and mutations of pathogens, such as during the COVID-19 pandemic. As these trends continue, the NGS market is set for substantial growth, fuelled by both technological advancements and a shift toward more personalized, data-driven healthcare.

Impact Analysis

The Canada next-generation sequencing (NGS) market has made an impact in the following ways:

Market Segmentation

Segmentation 1: by Offering

Based on offering, the Canada next-generation sequencing (NGS) market is led by equipment, which held a 45.39% share in 2023.

Segmentation 2: by Application

Based on application, the Canada next-generation sequencing (NGS) market is led by research, which held an 86.58% share in 2023.

Segmentation 3: by End User

Based on end users, the Canada next-generation sequencing (NGS) market is led by academic and research institutes, which held a 39.53% share in 2023.

Segmentation 4: by Technology

Based on technology, the Canada next-generation sequencing (NGS) market is led by sequencing by synthesis, which held a 75.09% share in 2023.

Segmentation 5: by Region

Recent Developments in the Canada Next-Generation Sequencing (NGS) Market

Demand: Drivers and Limitations

Market Demand Drivers

Increasing NGS-Based Testing Adoption in the Treatment of Cancer: The adoption of NGS-based minimal residual disease (MRD) testing in cancer care is rapidly increasing in Canada, driven by technological advancements, government support, and the growing demand for personalized medicine. NGS enables highly sensitive detection of residual cancer cells, allowing for earlier detection of relapse and more tailored treatment plans, which can significantly improve patient outcomes.

While challenges such as high costs, regulatory barriers, and the complexity of genomic data exist, the opportunities for improving cancer care are substantial. Continued investments in infrastructure, research, and collaboration are essential for overcoming these hurdles. By addressing these challenges, NGS-based MRD testing has the potential to transform cancer diagnostics and treatment, positioning Canada as a leader in genomic medicine and personalized oncology.

Increasing Government Initiatives: The Canadian Precision Health Initiative (CPHI) is a significant step forward in genomic healthcare, with substantial government investment aimed at providing personalized health solutions to Canadians while driving economic growth and ensuring data sovereignty. The initiative seeks to establish Canada as a global leader in genomic data collection, fostering innovations in precision medicine and improving healthcare accessibility.

Additionally, the Canadian Genomics Strategy emphasizes precision medicine, clean technology, and genomics innovation, positioning Canada to address critical healthcare challenges and contribute to sustainable economic growth. By advancing in genomics, Canada aims to lead global healthcare breakthroughs, offering tailored treatments and fostering new industries, while strengthening its role as a leader in healthcare technology and genomic research.

Market Restraints

High Costs and Resource Allocation: NGS-based testing offers significant clinical benefits, including personalized treatments for cancer, genetic disorders, and infectious diseases. However, the high costs of sequencing equipment, reagents, and bioinformatics infrastructure, along with the need for specialized training, present major barriers to widespread adoption, especially in rural and remote areas of Canada. To overcome these challenges, increased government support and investment are crucial. Funding can subsidize the cost of NGS technologies and enable the establishment of centralized resources, making the technology accessible to smaller healthcare providers.

Additionally, investments in training programs and research can reduce costs and enhance the efficiency of NGS. By addressing these barriers, NGS-based testing can become more accessible across Canada, improving healthcare equity and enabling personalized medicine for all Canadians.

Market Opportunities

Growing Advancements in Point-of-Care NGS: The increasing availability and affordability of portable NGS devices, such as the Oxford Nanopore MinION, present a transformative opportunity for the Canadian healthcare system, particularly in remote and under-resourced regions. These devices can revolutionize point-of-care diagnostics, enabling rapid and accurate testing for conditions such as rare diseases, cancer genomics, and infectious disease monitoring. In rural areas, where access to centralized labs is limited, the MinION allows healthcare providers to perform real-time sequencing on-site, speeding up diagnoses and treatment decisions.

For cancer care, it facilitates quicker detection of genetic mutations, enabling personalized treatment adjustments. In infectious disease monitoring, it enables swift genomic sequencing of pathogens, crucial for controlling outbreaks. The MinION's portability and cost-effectiveness make advanced diagnostic capabilities more accessible, offering equitable healthcare solutions and enhancing healthcare access across Canada, particularly in underserved regions.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, type portfolio, and market penetration. Some prominent names in the Canada next-generation sequencing (NGS) market include:

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/4ef3x5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment